Polycyclic Cbl-b Inhibitor for Autoimmune and Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases mediated by Cbl-b, such as autoimmune diseases and cancers, are limited in efficacy and specificity, highlighting the need for targeted therapeutic agents.
Innovation Solution
Development of a polycyclic compound that acts as a Cbl-b inhibitor, including stereoisomers and pharmaceutically acceptable salts, which can be used in pharmaceutical compositions to treat or prevent Cbl-b mediated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for Cbl-b mediated diseases, then treatment options are available, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies molecular parameters of the compound structure (formula I) to optimize binding affinity and selectivity for Cbl-b, thereby improving both efficacy and specificity simultaneously through structural parameter optimization
Solution Approach 2:
The invention creates a composite therapeutic approach by combining the polycyclic compound with pharmaceutical compositions and formulation excipients, achieving enhanced therapeutic efficacy while maintaining specificity through controlled drug delivery systems
2Adaptability or versatility
If targeted therapeutic agents are developed, then treatment specificity improves, but development complexity increases
Solution Approach 1:
The patent divides the complex polycyclic compound into distinct structural modules (formula I with defined substituents R1-R6, rings A-F, and linkers L1-L3), allowing systematic design and synthesis while maintaining high specificity for Cbl-b
Solution Approach 2:
The invention introduces specific functional groups and substituents at particular locations within the polycyclic structure to enhance binding affinity at the Cbl-b target site, achieving localized optimization without compromising overall molecular stability
Data Source
AI summary
The present application describes a polycyclic compound represented by general formula (I) as a Cbl-b inhibitor, or a stereoisomer or pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound of general formula (I) or the stereoisomer or pharmaceutically acceptable salt thereof, and a use of the compound of general formula (I) or the stereoisomer or pharmaceutically acceptable salt thereof, or the pharmaceutical composition in the prevention or treatment of diseases or conditions mediated by Cbl-b.